| アブストラクト | For management of osteoarticular infections, rifampicin appears to be the key antibiotic. We aimed to evaluate the actual rifampicin dosing regimens using a population pharmacokinetic model of rifampicin in patients with osteoarticular infections. A Monte Carlo simulation study was performed to simulate steady-state plasma concentrations for 1000 randomly sampled subjects using a total daily dose between 600 and 1200 mg (600 and 900 mg once daily, 450 and 600 mg twice daily, or 300 mg 3 times daily). When rifampicin was administered with fusidic acid, the pharmacokinetic/pharmacodynamic (PK/PD) target (area under the curve/minimum inhibitory concentration >/=952) was achieved with all tested dosing regimen, except 600 mg once daily for Staphylococcus epidermidis infections. Without coadministration of fusidic acid, none of tested dosing regimens achieved this PK/PD target. Most recommended drug-dosing regimens allow attaining the fixed area under the curve/minimum inhibitory concentration target for Staphylococcus aureus and coagulase-negative staphylococcal osteoarticular infections. In future studies, PK/PD target for osteoarticular infections in human should also be confirmed. |
|---|
| ジャーナル名 | British journal of clinical pharmacology |
|---|
| Pubmed追加日 | 2020/4/25 |
|---|
| 投稿者 | Marsot, Amelie; Menard, Amelie; Dupouey, Julien; Allanioux, Laurent; Blin, Olivier; Guilhaumou, Romain |
|---|
| 組織名 | Laboratoire de Suivi Therapeutique Pharmacologique et Pharmacocinetique, Faculte;de Pharmacie, Universite de Montreal, Montreal, Canada, QC.;Pole des Maladies Infectieuses et Tropicales, Fondation IHU Mediterranee;Infection, APHM, Marseille, France.;Service de Pharmacologie Clinique et Pharmacovigilance, Hopital de la Timone,;Marseille, France.;Aix Marseille Universite, Pharmacologie integree et interface clinique et;industrielle, Institut de Neuroscience des systemes, CNRS, 7289, Marseille,;France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32330996/ |
|---|
